Mecapegfilgrastim for Prevention of Chemotherapy-Induced Neutropenia in Advanced Breast Cancer
Key facts
- Where
- Hangzhou, ChinaSee the site
Where in China
- Zhejiang Cancer HospitalHangzhou, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Zheng Yabing
- Trial code
- NCT07899099
- Record updated
- 27 October 2026
- Original description
This prospective, real-world observational registry study will evaluate the effectiveness and safety of mecapegfilgrastim for the prevention of chemotherapy-induced neutropenia in patients with advanced breast cancer receiving chemotherapy. The decision to use mecapegfilgrastim will be made by the treating physician as part of routine clinical care. Participants will be followed to collect information on neutropenia, febrile neutropenia, treatment-related adverse events, and chemotherapy delivery.Read full original descriptionShow less
A Real-World Study of Mecapegfilgrastim for the Prevention of Chemotherapy-Induced Neutropenia in Advanced Breast Cancer
This prospective, real-world observational registry study will evaluate the effectiveness and safety of mecapegfilgrastim for the prevention of chemotherapy-induced neutropenia in patients with advanced breast cancer receiving chemotherapy. The decision to use mecapegfilgrastim will be made by the treating physician as part of routine clinical care. Participants will be followed to collect information on neutropenia, febrile neutropenia, treatment-related adverse events, and chemotherapy delivery.
Inclusion: Age 18 years or older; Histologically confirmed advanced breast cancer, defined as locally recurrent disease not suitable for curative treatment or metastatic disease; First recurrence or metastasis, or documented disease progression during palliative treatment, with a planned new systemic anticancer treatment regimen; Estimated life expectancy of at least 3 months; Ability and willingness to provide written informed consent.
Exclusion: Early-stage breast cancer; Any condition or other reason that, in the investigator's judgment, makes the participant unsuitable for enrollment; Ongoing systemic anticancer treatment without a need to change to a new treatment regimen; Pregnant or breastfeeding women.